Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

被引：0
|
作者：
Spelman, Lynda [1 ]
Warren, Richard B. [2 ]
Sofen, Howard [3 ]
Imafuku, Shinichi [4 ]
Blauvelt, Andrew [5 ]
Toms, Jessica [6 ]
Buck, Alex [7 ]
Banerjee, Subhashis [6 ]
Menter, Alan [8 ]
Szepietowski, Jacek C. [9 ]
机构：
[1] Verac Clin Res, Brisbane, Qld, Australia
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[3] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[4] Fukuoka Univ Hosp, Fukuoka, Japan
[5] Oregon Med Res Ctr, Portland, OR USA
[6] Bristol Myers Squibb, New York, NY USA
[7] Cytel Inc, Bristol Myers Squibb, Dallas, TX USA
[8] Baylor Univ, Med Ctr, Waco, TX 76798 USA
[9] Wroclaw Med Univ, Wroclaw, Poland
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [41] Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis
    Paller, Amy S.
    Siegfried, Elaine C.
    Pariser, David M.
    Rice, Kara Creamer
    Trivedi, Mona
    Iles, Jan
    Collier, David H.
    Kricorian, Greg
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (02) : 280 - 287
  • [42] Deucravacitinib Improves Dermatology Life Quality Index (DLQI) in Patients with Moderate to Severe Psoriasis: Results fromthe Phase 3 POETYK PSO-1 and PSO-2 Trials
    Augustin, Matthias
    Strober, Bruce
    Armstrong, April
    Beaumont, Jennifer
    Pham, Tan
    Hudgens, Stacie
    Zhuo, Joe
    Becker, Brandon
    Banerjee, Subhashis
    Kisa, Renata
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 112 - 112
  • [43] DEUCRAVACITINIB EFFICACY IN SPECIAL AREAS OF SCALP, FINGERNAILS, AND PALMS/SOLES IN PLAQUE PSORIASIS: RESULTS FROM A PHASE 3 TRIAL
    Bissonnette, Robert
    Armstrong, April W.
    Elewski, Boni
    Kisa, Renata M.
    Colombo, Matthew J.
    Ye, Cynthia
    Banerjee, Subhashis
    Blauvelt, Andrew
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [44] Long-term safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis type II: 2-year results from a phase 2/3 extension study
    Muenzer, Joseph
    Burton, Barbara K.
    Harmatz, Paul
    Gonzalez Gutierrez-Solana, Luis
    Ruiz-Garcia, Matilde
    Jones, Simon A.
    Guffon, Nathalie
    Inbar-Feigenberg, Michal
    Bratkovic, Drago
    Li, Xiaoxi
    Yee, Karen S.
    Alexanderian, David
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S73 - S74
  • [45] Safety of extended and long-term efalizumab therapy for plaque psoriasis: Results from phase III clinical trials
    Carey, W
    Menter, A
    Leonardi, C
    Lynde, C
    Ouellet, J
    Toth, D
    Rosoph, L
    Papp, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
  • [46] BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Thaci, Diamant
    Gottlieb, Alice B.
    Asahina, Akihiko
    Lebwohl, Mark
    McInnes, Iain B.
    Warren, Richard
    Boehncke, Wolf-Henning
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph F.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [47] Certolizumab pegol for plaque psoriasis: 2-year efficacy results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)
    Gordon, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Boehnlein, M.
    Kavanagh, S.
    Arendt, C.
    Gottlieb, A. B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB179 - AB179
  • [48] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial
    Imafuku, Shinichi
    Okubo, Yukari
    Tada, Yayoi
    Ohtsuki, Mamitaro
    Shao, Yanqiu
    Colston, Elizabeth
    Kisa, Renata M.
    Banerjee, Subhashis
    Morita, Akimichi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
  • [49] Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
    Megna, Matteo
    Ruggiero, Angelo
    Battista, Teresa
    Marano, Laura
    Cacciapuoti, Sara
    Potestio, Luca
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (09)
  • [50] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis: safety profile in older (≥ 65 years) and younger (< 65 years) patients in the phase III POETYK PSO-1, PSO-2 and long-term extension trials
    Kearney, Niamh
    Pink, Andrew
    Hoyt, Kim
    Kisa, Renata M.
    Banerjee, Subhashis
    Rogers, Alexandra
    Mullan, Jill
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I60 - I61
12345